Form 4: Acrivon Therapeutics COO Awarded Stock Options

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, was granted stock options for 90,090 shares at an exercise price of $5.70 on March 1, 2024.

Summary

• Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, was granted stock options to purchase 90,090 shares of common stock.
• The options have an exercise price of $5.70 per share.
• The grant date was March 1, 2024.
• The options vest over time, with 25% vesting on March 1, 2025, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The vesting is contingent upon Mr. Devroe's continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The stock option grant aligns the COO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the COO.

Future Outlook

The vesting schedule of the stock options is tied to the COO's continued service, suggesting a focus on long-term performance and stability.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year and the remainder over 36 months is a typical vesting structure.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the COO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity compensation, executive compensation, insider trading, Acrivon Therapeutics, ACRV, Eric Devroe